Institutional Investors Lead Shift in Portola Pharmaceuticals Inc (NASDAQ:PTLA) Sentiment

June 12, 2018 - By Maria Brooks

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Logo

Sentiment for Portola Pharmaceuticals Inc (NASDAQ:PTLA)

Portola Pharmaceuticals Inc (NASDAQ:PTLA) institutional sentiment decreased to 0.89 in 2018 Q1. Its down -0.47, from 1.36 in 2017Q4. The ratio dropped, as 75 active investment managers opened new or increased stock positions, while 84 sold and decreased their stakes in Portola Pharmaceuticals Inc. The active investment managers in our partner’s database now own: 55.00 million shares, down from 56.35 million shares in 2017Q4. Also, the number of active investment managers holding Portola Pharmaceuticals Inc in their top 10 stock positions decreased from 6 to 3 for a decrease of 3. Sold All: 37 Reduced: 47 Increased: 55 New Position: 20.

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company has market cap of $2.82 billion. The firm is developing Betrixaban, an oral once-daily inhibitor of Factor Xa that is in Phase III clinical stage for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use; Andexanet alfa, a recombinant protein, which is in Phase III and IV stages for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, an orally available dual kinase inhibitor, which is in Phase IIa clinical stage for hematologic, blood, cancers, and inflammatory disorders. It currently has negative earnings. It also develops Syk-selective inhibitors in pre-clinical stage for allergic conjunctivitis.

The stock increased 0.21% or $0.09 during the last trading session, reaching $42.9. About 566,110 shares traded. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has risen 7.75% since June 12, 2017 and is uptrending. It has underperformed by 4.82% the S&P500.

Analysts await Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) to report earnings on August, 8. They expect $-1.50 EPS, down 22.95 % or $0.28 from last year’s $-1.22 per share. After $-1.28 actual EPS reported by Portola Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 17.19 % negative EPS growth.

Fernwood Investment Management Llc holds 4.17% of its portfolio in Portola Pharmaceuticals, Inc. for 228,873 shares. Partner Fund Management L.P. owns 5.33 million shares or 3.53% of their US portfolio. Moreover, Partner Investment Management L.P. has 2.55% invested in the company for 72,284 shares. The New York-based Cadian Capital Management Lp has invested 2.19% in the stock. Harvey Capital Management Inc, a Florida-based fund reported 158,580 shares.

Since January 1, 0001, it had 0 buys, and 3 sales for $838,772 activity.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Ratings Coverage

Ratings analysis reveals 80% of Portola Pharma’s analysts are positive. Out of 5 Wall Street analysts rating Portola Pharma, 4 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $46 while the high is $80.0. The stock’s average target of $60 is 39.86% above today’s ($42.9) share price. PTLA was included in 13 notes of analysts from December 13, 2017. The firm has “Buy” rating given on Monday, January 15 by Oppenheimer. As per Wednesday, December 13, the company rating was maintained by Oppenheimer. The firm earned “Outperform” rating on Tuesday, March 13 by Credit Suisse. The firm has “Buy” rating by Oppenheimer given on Thursday, December 28. Oppenheimer maintained the stock with “Buy” rating in Tuesday, December 19 report. Cowen & Co maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) rating on Friday, May 4. Cowen & Co has “Buy” rating and $6500 target. The company was maintained on Tuesday, March 13 by Oppenheimer. Morgan Stanley maintained the stock with “Equal-Weight” rating in Monday, May 7 report. On Thursday, May 17 the stock rating was maintained by Oppenheimer with “Buy”. Morgan Stanley maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) rating on Thursday, February 22. Morgan Stanley has “Overweight” rating and $65 target.

More notable recent Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) news were published by: Seekingalpha.com which released: “Portola Pharmaceuticals’ (PTLA) CEO William Lis on Q1 2018 Results – Earnings Call Transcript” on May 15, 2018, also Globenewswire.com with their article: “Portola Pharmaceuticals Announces Retirement of CEO Bill Lis in 2018” published on June 04, 2018, Seekingalpha.com published: “Buy Diamondback Energy On Declines – Cramer’s Lightning Round (5/11/18)” on May 14, 2018. More interesting news about Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) were released by: Streetinsider.com and their article: “Portola Pharma (PTLA) Announces Retirement of CEO Bill Lis” published on June 04, 2018 as well as Fool.com‘s news article titled: “Is an Acquisition in Portola Pharmaceuticals’ Future?” with publication date: June 06, 2018.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.